 company profile The company is a high-precision medical industry cluster enterprise in regenerative medicine, specializing in special new technology enterprises. It has been a key project in Beijing for four consecutive years from 2017 to 2020, and is expected to realize the GEM IPO plan in 2024. The independently developed and mass-produced regenerated silicon RegeSi regenerative medicine material has broken the technological monopoly of developed countries in the field of regenerative medicine and filled the gap in regenerative medicine at home and abroad. It has applied for 62 invention patents and 14 international patents. It won the 2018 China Invention Patent Silver Award, and its technology is at the global leading level.  Enterprise Strength 2017-2020 for 4 consecutive years Listed as a key project in Beijing; Beijing’s “Specialized, Specialized and New” enterprise; State Intellectual Property Office Excellent cases of innovative development of TISC; Regenerative Medicine Bachelor’s Expert Workstation;Regenerative Medicine Postdoctoral Workstation;High-level talent studio for regenerative medicine materials;It has 20 full-time doctoral students, 22 academicians and experts participating in the support, and is preparing to establish a national regenerative medicine research center. Research Team "70th anniversary benchmark enterprise of medical industry since the founding of the People's Republic of China", "Beijing Invention and Innovation Award", "China Innovation and Entrepreneurship Competition new materials finals gold award", "Beijing Youth Innovation and Entrepreneurship Competition gold award", "Ranked first in Silicon Valley" To fill the gap in the domestic regenerative medicine field and achieve a world-leading position. The company is the only enterprise in the world capable of mass producing this new regenerative medicine material. Enterprise Honor Scientific Research Achievements  Regenerated silicon RegeSi has been included in the new materials catalog of the Ministry of Industry and Information Technology; the National Health Commission's key clinical promotion technology for wound repair. This material has the characteristics of promoting orderly growth of cells, promoting cell gene expression, realizing in-situ tissue regeneration, and quickly growing the same tissues and cells as the original ones. It is widely used in wound repair, chronic wounds, gynecological adhesion prevention, artificial bone, and nerve repair. , in vivo mucosa, bioloaded scaffolds (cartilage repair, targeted drug-loaded scaffolds), and medical aesthetics, it has been widely used in more than 10 high-end medical fields. The Xingfu Yisheng Regenerative Medicine R&D Center has a total area of 1,200 square meters and consists of four laboratories and a testing center, which are high-performance medical devices and sanitary disinfection product R&D laboratories, high-end daily chemical product R&D laboratories, and regenerative medicine material R&D experiments. laboratory, product pilot verification laboratory and product performance testing center. Xingfu Yisheng Regenerative Medicine R&D Center has technological innovation capabilities in regenerative medicine material design, new product development, product performance research, aseptic production and production line establishment. It is a basic research, engineering research and development center covering the main application fields of advanced regenerative medicine materials. An experimental and pilot-scale platform for early-stage industrialization research.
Beijing Obstetrics and Gynecology Hospital of Capital Medical University
General Hospital of the Chinese People's Liberation Army No.1 Hospital (304)
Beijing Jishuitan Hospital
National Cancer Center of China
Beijing Tiantan Hospital, Capital Medical University
The First Affiliated Hospital of Army Medical University (Southwest Hospital)
Peking Union Medical College Hospital
Peking University School and Hospital of Stomatology
|
